“Platelet like cells differentiated from human adipose derived mesenchymal stem cells promote healing of tendinopathy in rats” was published in Scientific Reports, which is an article on the therapeutic efficacy of human adipocyte-derived platelet-like cells manufactured using our basic techniques for tendinopathy.

 

https://www.nature.com/articles/s41598-025-99657-7

 

Tendinopathy is a chronic inflammation-based disorder of the musculotendinous attachments that move hands and fingers, including tendinitis and enthesitis. Tendinopathy has a predilection for the elbows, heels, shoulders, knees, and other joints of the extremities. It causes sharp pain during activities such as twisting the door knob and walking. It interferes not only with work and sports activities but also with daily activities. In general, tendinopathy is caused by repetitive movements in labor and sports, degeneration and micro-rupture of the tendon attachment due to aging, the symptoms do not improve once it develops, and it becomes intractable, and many cases suffer from pain for many years. A wide variety of therapies have been applied, including oral and external use of non-steroidal anti-inflammatory drugs, topical steroid injections, physical therapy, ultrasonic therapy, extracorporeal shock wave therapy, brace therapy, and surgical treatment, but no definitive treatment has yet been established.

 

AdipoSeeds was established in July 2016 to commercialize regenerative medicine products manufactured from human adipocyte-derived platelet-like cells based on the results of research by Professor Yumiko Matsubara of the Center for Sports Medicine, Keio University School of Medicine.

 

We have already completed clinical research at Keio University for the treatment of intractable skin ulcers by administrating human adipocyte-derived platelet-like cells, and we are now preparing for the early initiation of a clinical trial in Japan.

 

Human adipocyte-derived platelet-like cells are characterized by the abundant release of growth factors (cytokines) that are effective in tissue repair and regeneration. Therefore, we plan to expand our assets in the therapeutic fields related to tissue repair and regeneration, including tendinopathy.